TP53 and myelodysplastic syndrome: Recently a trial combining a TP53 inhibitor (APREA 246) in combination with azacitidine in TP53 mutant MDS showed a 100% response rate with 8/9 patients even achieving complete remission with median PFS and median OS not reached.